BioCryst Pharmaceuticals, Inc. (BCRX)

Market Cap	1.51B
Revenue (ttm)	450.71M
Net Income (ttm)	-88.88M
Shares Out	208.96M
EPS (ttm)	-0.43
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	189,110
Open	7.28
Previous Close	7.40
Day's Range	7.22 - 7.28
52-Week Range	4.03 - 9.50
Beta	1.75
Analysts	Buy
Price Target	15.67 (+117.04%)
Earnings Date	May 5, 2025

About BCRX

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and injectable protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhib...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Mar 3, 1994
• Employees: 580
• Stock Exchange: NASDAQ
• Ticker Symbol: BCRX
• Website: https://www.biocryst.com

Financial Performance

In 2024, BioCryst Pharmaceuticals's revenue was $450.71 million, an increase of 36.00% compared to the previous year's $331.41 million. Losses were -$88.88 million, -60.77% less than in 2023.

Analyst Forecast

According to 6 analysts, the average rating for BCRX stock is "Buy." The 12-month stock price forecast is $15.67, which is an increase of 117.04% from the latest price.

Price Target

$15.67

(117.04% upside)

Analyst Consensus: Buy